Precision fermentation is quietly becoming a supply chain strategy for biotech, not just a food tech story
Dr. Dereck Mush, MD, MBA
Ginkgo Bioworks
Cellular programming and synthetic biology platform for therapeutic and industrial use.
What they do
Ginkgo Bioworks designs and prints custom organisms for applications in therapeutics, agriculture, and industrial materials. The company provides genetic engineering services, allowing biotechnology firms to optimize cellular performance and produce novel proteins or compounds.
The record
- Vertical
- Biotech & Therapeutics
- Sub-segment
- Synthetic biology
- Product type
- Service
- Stage
- Public
- Headquarters
- Boston, USA
- Region
- North America
- Founded
- 2008
- Total funding
- $790M raised
Notable investors: Viking Global Investors, General Atlantic, Cascade Investment, Y Combinator.
Also in Biotech & Therapeutics
Related on The Signal
Dr. Dereck Mush, MD, MBA
AI is moving upstream, from molecule design into disease target identification itself
Dr. Dereck Mush, MD, MBA
Inside ReSCUED: UVM's $38M Blueprint for Critical Care Digital Twins
Dr. Dereck Mush, MD, MBA
Closing the Assay Loop: Inside Anthropic's $400M Wet Lab Pivot
Dr. Dereck Mush, MD, MBA